In early 2013, Freedom Meditech received FDA clearance for our CLEARPATH DS-120™ device that detects autofluorescence of the crystalline lens of the eye. In independent scientific studies published in peer-reviewed journals, elevated autofluorescence measurements have been linked to high levels of advanced glycosylated end products, which accumulate in the presence of diabetes. The evaluation using the CLEARPATH DS-120™ is quick and simple:
- Painless – The only one of its kind.
- Quick – No preparation required. Six second scan. Immediate results.
- Non-invasive – No blood or needles
In the U.S. there are about 25.8 million people with diabetes and another estimated 79 million with pre-diabetes. The Centers for Disease Control and Prevention estimate 90% of those with pre-diabetes don’t know they have the condition. Diabetes has significant end stage complications such as loss of sight, limbs or kidney function. And yet it has been established that early detection can stop disease complications with proper intervention and or treatment.
